Richard W Compans

US Patent:

6838080, Jan 4, 2005

Filed:

Dec 8, 2000

Appl. No.:

09/733166

Inventors:

Richard W. Compans - Atlanta GA, US
Zhiyi Sha - Atlanta GA, US

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 39145
A61K 3921
C12N 704
C12N 706

US Classification:

424 931, 242081, 24210, 24211, 242061, 24 933, 435236, 435238, 435 4, 435 5, 435 71, 435 72

Abstract:

The present disclosure provides methods and compositions for inducing an immune response to an antigen, especially in an immunogenic composition comprising sialic acid where the antigen comprises sialic acid and wherein the immunogenic composition further comprises a sialic acid binding component, e. g. , an inactivated or attenuated paramyxovirus or orthomyxovirus such as an influenza virus comprising a sialic acid binding component, e. g. , a neuraminidase. The compositions comprising sialic acid and a sialic acid binding component effectively induce a humoral immune response even in a human or animal which is deficient in CD4+ T cells, due to a disease such as ARC or AIDS, and there is also an immunoglobulin class switching even in the absence of CD4+ T cells.

US Patent:

20010036463, Nov 1, 2001

Filed:

Mar 9, 2001

Appl. No.:

09/803649

Inventors:

Richard Compans - Atlanta GA, US
Zhiyi Sha - Brooklyn NY, US

International Classification:

A61K039/12
A61K031/715

US Classification:

424/204100, 514/054000

Abstract:

The present Specification discloses noninvasive, economical and easy methods for inducing an immune response against a particulate antigen; i.e., by transcutaneous administration of the particulate antigen such as a virus particle which has desirably been inactivated or attenuated so as not be result in a disease in the person or animal to which it has been administered. Advantageously, the immunogenic composition comprises a sialic binding component (such as a viral hemagglutinin) included as part of or in addition to the particulate antigen. One such example of a particulate virus is influenza virus, desirable having been formalin-inactivated.

US Patent:

20030092665, May 15, 2003

Filed:

Sep 13, 2002

Appl. No.:

10/243472

Inventors:

Richard Compans - Atlanta GA, US

International Classification:

A61K048/00
A61K009/127
C12N015/86
C12N015/88

US Classification:

514/044000, 424/450000, 435/456000, 435/458000

Abstract:

The present invention provides an economical, nontraumatic and surprisingly effective method for producing a desired protein (especially a biologically active protein) or an antigen using nucleic acid molecules encoding the protein or antigen delivered to a mucosal surface of the animal or human. Expression of the antigen coding sequence exposes the immune system of the animal or human to the antigen with the result that an immune response results, especially an antigen-specific IgA response at mucosal surfaces. Desirably, the nucleic acid molecules are formulated with a bioadhesive agent in an amount sufficient to improve adherence to cells at the mucosal surfaces, thereby improving uptake of the nucleic acid molecules.

US Patent:

20050090428, Apr 28, 2005

Filed:

Jan 8, 2003

Appl. No.:

10/500884

Inventors:

Richard Compans - Atlanta GA, US
Luigi Marzilli - Baton Rouge LA, US
Amy Sears - St. Petersburg FL, US
Dabbey Dixon - Atlanta GA, US

Assignee:

Emory University - Atlanta GA
Georgia State University Research Foundation, Inc - Atlanta GA

International Classification:

A61K038/16
A61K031/675
A61K031/555
A61K031/4439
A61K031/4178
A61K031/409

US Classification:

514006000, 514185000, 514081000, 514338000, 514397000, 514410000

Abstract:

Compositions and methods of using thereof for the prevention of sexually transmitted diseases resulting from infection with one or more of viral pathogens have been developed. The compositions contain one or more porphyrins, tetrapyrrole macrocycle compounds with bridges of one carbon joining the pyrroles. In a preferred embodiment, the compositions are administered in a formulation suitable for administration to a mucosal surface.

US Patent:

20060088909, Apr 27, 2006

Filed:

May 19, 2003

Appl. No.:

10/514462

Inventors:

Richard Compans - Atlanta GA, US
Chinglai Yang - Decatur GA, US
Qizhi Yao - Houston TX, US

International Classification:

C12Q 1/68
C12P 21/06

US Classification:

435069100, 435006000

Abstract:

Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of liciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The viral protein and the viral surface envelope glycoprotein are from different viruses. Another VLP can include a viral core protein that can self assemble into a VLP core; at least one viral surface envelope glycoprotein expressed on the surface of the VLP; and at least one adjuvant molecule expressed on the surface of the VLP.

US Patent:

20060216702, Sep 28, 2006

Filed:

Apr 4, 2006

Appl. No.:

11/397830

Inventors:

Richard Compans - Atlanta GA, US
Chinglai Yang - Decatur GA, US
Qizhi Yao - Houston TX, US

International Classification:

C12Q 1/70
A61K 39/12
C12N 7/00

US Classification:

435005000, 424186100, 435235100, 424204100, 977802000

Abstract:

Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The VLP can also optionally include at least one adjuvant molecule expressed on the surface of the VLP.

US Patent:

20100047277, Feb 25, 2010

Filed:

Jul 12, 2007

Appl. No.:

12/373595

Inventors:

Richard W. Compans - Atlanta GA, US
Chinglai Yang - Decatur GA, US
Qizhi Yao - Houston TX, US

International Classification:

A61K 39/12
A61K 39/21
A61K 39/145
A61K 39/155
A61K 39/215
A61K 39/205
A61K 39/245
A61K 39/25
C12Q 1/70
C12N 15/00
A61P 31/12

US Classification:

4242081, 4242041, 4242071, 4242091, 4242111, 4242181, 4242211, 4242241, 4242291, 4242301, 435 5, 435455

Abstract:

Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one viral surface envelope glycoprotein expressed on the surface of the virosome. The virosome can also optionally include at least one adjuvant molecule expressed on the surface of the virosome.

US Patent:

20100196419, Aug 5, 2010

Filed:

May 2, 2008

Appl. No.:

12/598271

Inventors:

Richard W. Compans - Atlanta GA, US
Baozhong Wang - Atlanta GA, US
Beatrice Hahn - Birmingham AL, US
Weimin Liu - Hoover AL, US
Gale Smith - Gaithersburg MD, US
Peter Pushko - Frederick MD, US

International Classification:

A61K 39/12
C07H 21/04
C12N 15/63
C12N 7/01
C12P 21/06

US Classification:

4242041, 536 2372, 4353201, 4352351, 435 691

Abstract:

Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.